DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 7,507,570 B2 Prabhakar Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 7,507,570 B2 Prabhakar Et Al USOO750757OB2 (12) United States Patent (10) Patent No.: US 7,507,570 B2 Prabhakar et al. (45) Date of Patent: Mar. 24, 2009 (54) RECOMBINANT CHONDROITINASE ABC I 6,184,023 B1 2/2001 Hashimoto et al. AND USES THEREOF 6,217,863 B1 4/2001 Godavarti et al. 6,597,996 B1 7/2003 Venkataraman et al. (75) Inventors: Vikas Prabhakar, Cambridge, MA 6,869,789 B2 3/2005 Liu et al. (US); Ishan Capila, Ashland, MA (US); 6,962,699 B2 * 1 1/2005 Pojasek et al. ............. 424,945 Rahul Raman, Arlington, MA (US); 29:W w- R 3. Silvaasisekharan et al. Carlos Bosques, Cambridge, MA (US); 7,105,334 B2 9/2006 Pojasek et al. Kevin Pojasek, Cambridge, MA (US); 7,110,889 B2 9/2006 Venkataraman et al. Ram Sasisekharan, Bedford, MA (US) 7,117,100 B2 10/2006 Venkataraman et al. 7,129,335 B2 10/2006 Pojasek et al. (73) Assignee: Massachusetts Institute of Technology, 7,139,666 B2 11/2006 Venkataraman et al. Cambridge, MA (US) 7,247.445 B2 7/2007 Sasisekharan et al. 7,270,815 B2 9/2007 Sasisekharan et al. (*) Notice: Subject to any disclaimer, the term of this 2002/O122793 A1 9, 2002 Liu et al. patent is extended or adjusted under 35 2002/O128225 A1 9, 2002 Liu et al. 2002fO169143 A1 11/2002 Sasisekharan et al. U.S.C. 154(b) by 0 days. 2003, OOO8820 A1 1/2003 Kwan et al. 2003.0099628 A1 5/2003 Liu et al. (21) Appl. No.: 11/078,915 2003/O191587 A1 10/2003 Venkataraman et al. 2004/0091471 A1 5/2004 Myette et al. (22) Filed: Mar 10, 2005 2004/0091472 A1 5/2004 Pojasek et al. 2004/0092037 A1 5/2004 Sasisekharan et al. (65) Prior Publication Data US 2006/0078959 A1 Apr. 13, 2006 (Continued) FOREIGN PATENT DOCUMENTS Related U.S. Application Data EP O 576 294 A2 12, 1993 (60) Provisional application No. 60/552,232, filed on Mar. EP O 613 949 A2 9, 1994 10, 2004, provisional application No. 60/578,917, JP 20000446O1 A 2, 2000 filed on Jun. 10, 2004, provisional application No. WO WO 94,25567 A1 11F1994 60/625,052, filed on Nov. 3, 2004. WO WO 96,01894 A1 1, 1996 WO WO97, 16556 A1 5, 1997 (51) Int. Cl. Continued CI2N 9/88 (2006.01) (Continued) CI2N 9/00 (2006.01) OTHER PUBLICATIONS CI2N 15/70 (2006.01) Huang et al. Crystal structure of Proteus Vulgaris chondroitin Sulfate CI2O I/68 (2006.01) ABC 1yase I at 1.9A resolution. DJ Mol Biol. May 2, CI2P 19/28 (2006.01) 2003:328(3):623-34.* CI2P 2/06 (2006.01) Michel et al. The structure of chondroitin B lyase complexed with C7H 2L/04 (2006.01) glucosaminoglycan oligosaccharides unravels a calcium-dependent (52) U.S. Cl. ....................... 435/232; 435/183; 435/200; catalytic machinery, J Biol Chem. Jul 30, 2004:279(31):32882-96. 435/6: 435/18: 435/85; 435/69. 1; 435/320.1; Epub May 21, 2004.* 536/23.2; 424/94.5 (Continued) (58) Field of Classification Search ................. 435/200, 435/18, 85, 69.1, 320.1; 536/23.2 Primary Examiner Rebecca E Prouty See application file for complete search history. Assistant Examiner Iqbal H Chowdhury (74) Attorney, Agent, or Firm Wolf, Greenfield & Sacks, (56) References Cited P.C. U.S. PATENT DOCUMENTS (57) ABSTRACT 5,198.855 A 3, 1993 Iwai 5,292,509 A 3/1994 Hageman The invention relates to chondroitinase ABC I and uses 5,496,718 A 3, 1996 Hashimoto et al. thereof. In particular, the invention relates to recombinant and 5,498,536 A 3, 1996 Khandke modified chondroitinase ABC I, their production and their 5,525,500 A 6, 1996 Khandke et al. uses. The chondroitinase ABC I enzymes of the invention are 5,578.480 A 11/1996 Khandke useful for a variety of purposes, including degrading and 5,716,617 A 2f1998 Khandke et al. analyzing polysaccharides Such as glycosaminoglycans 5,741,692 A * 4, 1998 Khandke et al. ............ 435/200 5,763,205 A 6, 1998 Hashimoto et al. (GAGs). These GAGs can include chondroitin sulfate, der 5,773,277 A 6, 1998 Hashimoto et al. matan Sulfate, unsulfated chondroitin and hyaluronan. The 5,888,798 A 3, 1999 Lotvin et al. chondroitinase ABC I enzymes can also be used in therapeu 5.997,863 A 12, 1999 Zimmermann et al. tic methods such as promoting nerve regeneration, promoting 6,001,630 A 12/1999 Ichikawa et al. stroke recovery, treating spinal cord injury, treating epithelial 6,007,810 A 12/1999 Ishikawa et al. disease, treating infections and treating cancer. 6,054,569 A 4/2000 Bennett et al. 6,093,563 A 7/2000 Bennett et al. 20 Claims, 27 Drawing Sheets US 7,507,570 B2 Page 2 U.S. PATENT DOCUMENTS No Author Listed NCBI database, Structure Summary 1DBO, Crystal Structure of Chondroitinase B, MMDB No. 12452. Deposi 2004/O197933 A1 10/2004 Venkataraman et al. tion date Nov. 3, 1999, 1 page. 2004/0204869 A1 10/2004 Venkataraman et al. No Author Listed Protein Data Bank, Structure Explorer - 1DBO, 2005/0O3.7376 A1 2/2005 Sasisekharan et al. "Crystal Structure of Chondroitinase B” http://www.rcbs.org/pdb/ 2005, 0118157 A1 6, 2005 McMahon et al. cgi/explore.cgi/ex;ore.cgi?pdb.Id=1DBO, Deposition dated Nov. 3, 2005/0227320 A1 10/2005 Pojaseket al. 1999; Release date Jan. 12, 2000; printed Feb. 23, 2005, 1 page. 2005/0233402 A1 10/2005 Liu et al. No Author Listed Structure Summary Prinout for 1dbo, http:// 2005/0233419 A1 10/2005 Pojaseket al. pdbbeta.rcsb.org/pdb/explore.do?structureId=1dbo, Deposition date 2006.0024664 A1 2, 2006 Sasisekharan et al. Nov. 3, 1999; Release date Jan. 12, 2000; printed Feb. 23, 2005, 1 2006/0057638 A1 3/2006 Bosques et al. page. 2006, OO67927 A1 3/2006 Chandrasekaran et al. No Author Listed MMDB Summary Printout for 1HM2, http:// 2006, OO67928 A1 3, 2006 Liu et al. pdbbeta.rcsb.org/pdb/explore.do?structureId=1hm2, Deposition 2006, OO78959 A1 4/2006 Prabhakar et al. date Dec. 4, 2000; Release date May 2, 2001; printed Feb. 23, 2005, 2006, 0083711 A1 4/2006 Berry et al. 1 pages. 2006, O10543.0 A1 5/2006 Sasisekharan et al. No Author Listed Protein Data Bank, Structure Explorer - 1HM2, 2006/O12795.0 A1 6/2006 Bosques et al. "Active Site of Chondroitinase Ac Lyase Revealed by The Structure 2006, O154337 A1 7/2006 Sato et al. of Enzyme-Oligosaccharide Complexes and Mutagenesis'. http:// 2006, O154894 A1 7/2006 Berry et al. www.rcsb.org/pdb/cgi/explore.cgi?pdb.Id=1HM2, Deposition date 2006/0177885 A1 8/2006 Myette et al. Dec. 4, 2000; Release date May 2, 2001; printed Feb. 23, 2005, 1 2006/017791.0 A1 8/2006 Myette et al. page. 2006/0177911 A1 8/2006 Myette et al. No Author Listed NCBI Database, Structure Summary for 1HM2, 2006, O182734 A1 8, 2006 Liu et al. Crystal Structure of Chondroitinase B, MMDB No. 16157. Deposi 2006, O183713 A1 8, 2006 Liu et al. tion date Dec. 4, 2000; 1 page. 2006, O183891 A1 8/2006 Myette et al. No Author Listed MMDB Summary Printout for 1 plu, “Pectate 2006/0233782 A1 10, 2006 Gruskin et al. Lyase CFrom Erwinia ChrysanthemiWith 1 LU+3 Ion in the Putative 2006, O292130 A1 12/2006 Sasisekharan et al. Calcium Binding Site'. http://pdbbeta.rcsb.org/pdb/explore. 2006/0292655 A1 12/2006 Sasisekharan et al. do?structureId=1plu, Deposition date Jun. 4, 1999; Release date Jul. 2006/029.2673 A1 12/2006 Sasisekharan et al. 13, 1999; printed Feb. 23, 2005, 1 page. 2007,0004012 A1 1/2007 Sasisekharan et al. No Author Listed NCBI database, Structural Summary for 1DBG, 2007/0020243 A1 1/2007 Sengupta et al. Crystal Structure of Chondroitinase B, MMDB No. 12451. Deposi 2007/0065424 A1 3/2007 Pojasek et al. tion date Nov. 2, 1999, 1 page. 2007/0065921 A1 3/2007 Sasisekharan et al. No Author Listed Structure Summary Printout for 1dbg. http:// 2007/0066769 A1 3/2007 Venkataraman et al. pdbbeta.rcsb.org/pdb/explore.do?structureId=ldbg. Deposition date 2007/O148157 A1 6, 2007 Prabhakar et al. Nov. 2, 1999; Release date Jan. 12, 2000; printed Feb. 23, 2005, 1 2007. O1481.58 A1 6/2007 Sasisekharan et al. page. 2007. O14874.0 A1 6, 2007 Prabhakar et al. No Author Listed Protein Data Bank, Structure Explorer - 1DBG, 2007/O161073 A1 7/2007 Sasisekharan et al. "Crystal Structure of Chondroitinase B'. http://www.rcsb.org/pdb/ 2007/0202563 A1 8, 2007 Prabhakar et al. cgi/explore.cgi?pdb.Id=1DBG, Deposition date Nov. 2, 1999; 2007/0224670 A1 9, 2007 Prabhakar et al. Release date Jan. 12, 2000; printed Feb. 23, 2005, 1 page. No Author Listed NCBI database, Protein 1HNOA Chain A. Crystal FOREIGN PATENT DOCUMENTS Structure of Chondroitinase Abc Lyase I From Proteus Vulgaris. At 1.9 Angstroms Resolution, gi: 30749254. BTC Oct. 1, 2007, 6 pages. WO WOOOf 12726 A2 3, 2000 No Author Listed NCBI database, "Pedobacter Heparinus WO WOOOf 65521 A2 11/2000 Chondroitinase B Precursor (cs1B) gene Complete cols'. Accession WO WOO1/35977 A2 5, 2001 No. U27584.1 GI: 1002526. BCT Jan. 6, 2000, 2 pages. WO WOO1,66772 A2 9, 2001 No Author Listed NCB database, “Sequence 2 from patent US WO WOO2,23190 A2 3, 2002 5578480”. Accession No. AAB43331; PAT Feb. 7, 1997, 1 page.
Load more

Recommended publications
  • BIOCELL - Volume 29 - Supplement - December 2005 - Mendoza, Argentina
    B I O C E L L formerly ELECTRON MICROSCOPY AND CELL BIOLOGY Official journal of the Sociedades Latinoamericanas de Microscopía Electrónica (SLAME), Iberoamericana de Biología Celular (SIABC), Federación Iberoamericana de Biología Celular y Molecular, and Sociedad Argentina de Investigaciones en Bioquímica y Biología Molecular (SAIB). BIOCELL - Volume 29 - Supplement - December 2005 - Mendoza, Argentina. Recently BIOCELL has signed an agreement with the new Electronic Library Project of the Institute for Scientific Information (ISI) Philadelphia Pennsylvania USA. ISSN 0327 - 9545 (print) - ISSN 1667 - 5746 (electronic) This journal is included in the Life Sciences Edition Contents, the Science Citation Index, Scisearch and Research Alert databases of Current Content; ISI/BIOMED, Index Medicus and MEDLINE available on the NLM's on line MED'LARS systems; EMBASE/ Excerpta Medica; Chemical Abstracts, Biological Abstracts (BIOSIS), Index Medicus for Latin America and LATINDEX. EDITORS Editors in Chief: Mario H. Burgos Ramón S. Piezzi Instituto de Histología y Embriología “Dr. Mario H. Burgos” (IHEM-CONICET), Facultad de Ciencias Médicas, Universidad Nacional de Cuyo, Mendoza, Argentina. Editorial Staff: Alfredo J. Castro Vázquez Bruno Cavagnaro Juan Carlos Cavicchia María Isabel Colombo Juan Carlos de Rosas Miguel Walter Fornés Luis S. Mayorga Roberto Yunes Editorial Board: A. Aoki (Argentina) E.W. Kitajima (Brasil) S.N. Báo (Brasil) F. Leighton (Chile) H.S. Barra (Argentina) M.E. Manes (Argentina) C. Barros (Chile) R.W. Masuelli (Argentina) N. Bianchi (Argentina) B. Meyer-Rochow (Alemania) R. Bottini (Argentina) C.R. Morales (Canadá) E. Bustos Obregón (Chile) C.B. Passera (Argentina) O.J. Castejón (Venezuela) E. Rodríguez Echandía (Argentina) F. Roig (Argentina) H. Chemes (Argentina) R.A.
    [Show full text]
  • The Crystal Structure of Novel Chondroitin Lyase ODV-E66, A
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector FEBS Letters 587 (2013) 3943–3948 journal homepage: www.FEBSLetters.org The crystal structure of novel chondroitin lyase ODV-E66, a baculovirus envelope protein ⇑ Yoshirou Kawaguchi a, Nobuo Sugiura b, Koji Kimata c, Makoto Kimura a,d, Yoshimitsu Kakuta a,d, a Laboratory of Structural Biology, Graduate School of System Life Sciences, Kyushu University, 6-10-1 Hakozaki, Fukuoka 812-8581, Japan b Institute for Molecular Science of Medicine, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, Aichi 480-1195, Japan c Research Complex for the Medicine Frontiers, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, Aichi 480-1195, Japan d Faculty of Agriculture, Kyushu University, 6-10-1 Hakozaki, Fukuoka 812-8581, Japan article info abstract Article history: Chondroitin lyases have been known as pathogenic bacterial enzymes that degrade chondroitin. Received 5 August 2013 Recently, baculovirus envelope protein ODV-E66 was identified as the first reported viral chondroi- Revised 1 October 2013 tin lyase. ODV-E66 has low sequence identity with bacterial lyases at <12%, and unique characteris- Accepted 15 October 2013 tics reflecting the life cycle of baculovirus. To understand ODV-E66’s structural basis, the crystal Available online 26 October 2013 structure was determined and it was found that the structural fold resembled that of polysaccharide Edited by Christian Griesinger lyase 8 proteins and that the catalytic residues were also conserved. This structure enabled discus- sion of the unique substrate specificity and the stability of ODV-E66 as well as the host specificity of baculovirus.
    [Show full text]
  • Manual D'estil Per a Les Ciències De Laboratori Clínic
    MANUAL D’ESTIL PER A LES CIÈNCIES DE LABORATORI CLÍNIC Segona edició Preparada per: XAVIER FUENTES I ARDERIU JAUME MIRÓ I BALAGUÉ JOAN NICOLAU I COSTA Barcelona, 14 d’octubre de 2011 1 Índex Pròleg Introducció 1 Criteris generals de redacció 1.1 Llenguatge no discriminatori per raó de sexe 1.2 Llenguatge no discriminatori per raó de titulació o d’àmbit professional 1.3 Llenguatge no discriminatori per raó d'ètnia 2 Criteris gramaticals 2.1 Criteris sintàctics 2.1.1 Les conjuncions 2.2 Criteris morfològics 2.2.1 Els articles 2.2.2 Els pronoms 2.2.3 Els noms comuns 2.2.4 Els noms propis 2.2.4.1 Els antropònims 2.2.4.2 Els noms de les espècies biològiques 2.2.4.3 Els topònims 2.2.4.4 Les marques registrades i els noms comercials 2.2.5 Els adjectius 2.2.6 El nombre 2.2.7 El gènere 2.2.8 Els verbs 2.2.8.1 Les formes perifràstiques 2.2.8.2 L’ús dels infinitius ser i ésser 2.2.8.3 Els verbs fer, realitzar i efectuar 2.2.8.4 Les formes i l’ús del gerundi 2.2.8.5 L'ús del verb haver 2.2.8.6 Els verbs haver i caldre 2.2.8.7 La forma es i se davant dels verbs 2.2.9 Els adverbis 2.2.10 Les locucions 2.2.11 Les preposicions 2.2.12 Els prefixos 2.2.13 Els sufixos 2.2.14 Els signes de puntuació i altres signes ortogràfics auxiliars 2.2.14.1 La coma 2.2.14.2 El punt i coma 2.2.14.3 El punt 2.2.14.4 Els dos punts 2.2.14.5 Els punts suspensius 2.2.14.6 El guionet 2.2.14.7 El guió 2.2.14.8 El punt i guió 2.2.14.9 L’apòstrof 2.2.14.10 L’interrogant 2 2.2.14.11 L’exclamació 2.2.14.12 Les cometes 2.2.14.13 Els parèntesis 2.2.14.14 Els claudàtors 2.2.14.15
    [Show full text]
  • Analysis of Glycosaminoglycans with Polysaccharide Lyases
    Analysis of Glycosaminoglycans with UNIT 17.13B Polysaccharide Lyases Polysaccharide lyases are a class of enzymes useful for analysis of glycosaminoglycans (GAGs) and the glycosaminoglycan component of proteoglycans (PGs). These enzymes cleave specific glycosidic linkages present in acidic polysaccharides and result in depo- lymerization (Linhardt et al., 1986). These enzymes act through an eliminase mechanism resulting in unsaturated oligosaccharide products that have UV absorbance at 232 nm. The lyases are derived from a wide variety of pathogenic and nonpathogenic bacteria and fungi (Linhardt et al., 1986). This class of enzymes includes heparin lyases (heparinases), heparan sulfate lyases (heparanases or heparitinases), chondroitin lyases (chondroiti- nases), and hyaluronate lyases (hyaluronidases), all of which are described in this unit. Polysaccharide lyases can be used, alone or in combinations, to confirm the presence of GAGs in a sample as well as to distinguish between different GAGs (see Table 17.13B.1 and Commentary). The protocols given for heparin lyase I are general and, with minor modifications (described for each lyase and summarized in Table 17.13B.2), can be used for any of the polysaccharide lyases. The basic protocol describes depolymerization of GAGs in samples containing 1 µg to 1 mg of GAGs. The alternate protocol describes depolymerization of GAGs in samples containing <1 µg of radiolabeled GAG. Two support protocols describe assays to confirm and quantitate the activity of heparin and chondroitin ABC lyases. It is recommended that enzyme activity be assayed before the enzyme is used in an experiment to be sure it is active and has been stored properly. The standard definition of a unit (U), 1 µmol product formed/min, is used throughout this µ ∆ article.
    [Show full text]
  • 12) United States Patent (10
    US007635572B2 (12) UnitedO States Patent (10) Patent No.: US 7,635,572 B2 Zhou et al. (45) Date of Patent: Dec. 22, 2009 (54) METHODS FOR CONDUCTING ASSAYS FOR 5,506,121 A 4/1996 Skerra et al. ENZYME ACTIVITY ON PROTEIN 5,510,270 A 4/1996 Fodor et al. MICROARRAYS 5,512,492 A 4/1996 Herron et al. 5,516,635 A 5/1996 Ekins et al. (75) Inventors: Fang X. Zhou, New Haven, CT (US); 5,532,128 A 7/1996 Eggers Barry Schweitzer, Cheshire, CT (US) 5,538,897 A 7/1996 Yates, III et al. s s 5,541,070 A 7/1996 Kauvar (73) Assignee: Life Technologies Corporation, .. S.E. al Carlsbad, CA (US) 5,585,069 A 12/1996 Zanzucchi et al. 5,585,639 A 12/1996 Dorsel et al. (*) Notice: Subject to any disclaimer, the term of this 5,593,838 A 1/1997 Zanzucchi et al. patent is extended or adjusted under 35 5,605,662 A 2f1997 Heller et al. U.S.C. 154(b) by 0 days. 5,620,850 A 4/1997 Bamdad et al. 5,624,711 A 4/1997 Sundberg et al. (21) Appl. No.: 10/865,431 5,627,369 A 5/1997 Vestal et al. 5,629,213 A 5/1997 Kornguth et al. (22) Filed: Jun. 9, 2004 (Continued) (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2005/O118665 A1 Jun. 2, 2005 EP 596421 10, 1993 EP 0619321 12/1994 (51) Int. Cl. EP O664452 7, 1995 CI2O 1/50 (2006.01) EP O818467 1, 1998 (52) U.S.
    [Show full text]
  • POLSKIE TOWARZYSTWO BIOCHEMICZNE Postępy Biochemii
    POLSKIE TOWARZYSTWO BIOCHEMICZNE Postępy Biochemii http://rcin.org.pl WSKAZÓWKI DLA AUTORÓW Kwartalnik „Postępy Biochemii” publikuje artykuły monograficzne omawiające wąskie tematy, oraz artykuły przeglądowe referujące szersze zagadnienia z biochemii i nauk pokrewnych. Artykuły pierwszego typu winny w sposób syntetyczny omawiać wybrany temat na podstawie możliwie pełnego piśmiennictwa z kilku ostatnich lat, a artykuły drugiego typu na podstawie piśmiennictwa z ostatnich dwu lat. Objętość takich artykułów nie powinna przekraczać 25 stron maszynopisu (nie licząc ilustracji i piśmiennictwa). Kwartalnik publikuje także artykuły typu minireviews, do 10 stron maszynopisu, z dziedziny zainteresowań autora, opracowane na podstawie najnow­ szego piśmiennictwa, wystarczającego dla zilustrowania problemu. Ponadto kwartalnik publikuje krótkie noty, do 5 stron maszynopisu, informujące o nowych, interesujących osiągnięciach biochemii i nauk pokrewnych, oraz noty przybliżające historię badań w zakresie różnych dziedzin biochemii. Przekazanie artykułu do Redakcji jest równoznaczne z oświadczeniem, że nadesłana praca nie była i nie będzie publikowana w innym czasopiśmie, jeżeli zostanie ogłoszona w „Postępach Biochemii”. Autorzy artykułu odpowiadają za prawidłowość i ścisłość podanych informacji. Autorów obowiązuje korekta autorska. Koszty zmian tekstu w korekcie (poza poprawieniem błędów drukarskich) ponoszą autorzy. Artykuły honoruje się według obowiązujących stawek. Autorzy otrzymują bezpłatnie 25 odbitek swego artykułu; zamówienia na dodatkowe odbitki (płatne) należy zgłosić pisemnie odsyłając pracę po korekcie autorskiej. Redakcja prosi autorów o przestrzeganie następujących wskazówek: Forma maszynopisu: maszynopis pracy i wszelkie załączniki należy nadsyłać w dwu egzem­ plarzach. Maszynopis powinien być napisany jednostronnie, z podwójną interlinią, z marginesem ok. 4 cm po lewej i ok. 1 cm po prawej stronie; nie może zawierać więcej niż 60 znaków w jednym wierszu nie więcej niż 30 wierszy na stronie zgodnie z Normą Polską.
    [Show full text]
  • Desarrollo Y Aplicación De Herramientas Computacionales Para El Análisis Taxonómico Y Patogenómico De Procariotas
    Tesis de Doctorado en Biología (PEDECIBA) Subárea Biología Celular y Molecular Desarrollo y aplicación de herramientas computacionales para el análisis taxonómico y patogenómico de procariotas October 11, 2016 Unidad de Bioinformática Institut Pasteur Montevideo Autor GREGORIO IRAOLA Orientador HUGO NAYA Tribunal Elena Fabiano (Presidente) Alejandro Buschiazzo (Vocal) Héctor Romero (Vocal) 3 Prefacio En esta Tesis se presentan de forma unificada las actividades de inves- tigación llevadas a cabo en la Unidad de Bioinformática (en colaboración con otras instituciones locales y extranjeras) entre los años 2010 y 2016. Estas actividades comenzaron en el marco de mi Maestría en Bioinformática (PEDECIBA), donde desarrollé algunas aproximaciones para la predicción de patogenicidad a partir del análisis de genomas bacterianos. Estos resultados dieron lugar a una línea de investigación dedicada al estudio genómico de microorganismos y a optar por el pasaje al programa de Doctorado en Biología, subárea Biología Celular y Molecular (PEDECIBA) en 2014. En estos seis años de formación de posgrado he continuado con el desarrollo y aplicación herramientas de biología computacional para el análisis de geno- mas procariotas, con el objetivo específico de responder preguntas generales y particulares acerca de la clasificación taxonómica de los procariotas y su patogenicidad utilizando datos producidos por tecnologías de secuenciación masiva. El hilo conductor de la Tesis es el estudio de genomas procariotas por medios computacionales aunque, debido a la diversidad de temas especí- ficos abordados, la misma ha sido dividida en tres partes y un total de diez capítulos. Cada capítulo representa en su totalidad un artículo científico ya publicado o en vías de publicación en revistas científicas internacionales.
    [Show full text]
  • All Enzymes in BRENDA™ the Comprehensive Enzyme Information System
    All enzymes in BRENDA™ The Comprehensive Enzyme Information System http://www.brenda-enzymes.org/index.php4?page=information/all_enzymes.php4 1.1.1.1 alcohol dehydrogenase 1.1.1.B1 D-arabitol-phosphate dehydrogenase 1.1.1.2 alcohol dehydrogenase (NADP+) 1.1.1.B3 (S)-specific secondary alcohol dehydrogenase 1.1.1.3 homoserine dehydrogenase 1.1.1.B4 (R)-specific secondary alcohol dehydrogenase 1.1.1.4 (R,R)-butanediol dehydrogenase 1.1.1.5 acetoin dehydrogenase 1.1.1.B5 NADP-retinol dehydrogenase 1.1.1.6 glycerol dehydrogenase 1.1.1.7 propanediol-phosphate dehydrogenase 1.1.1.8 glycerol-3-phosphate dehydrogenase (NAD+) 1.1.1.9 D-xylulose reductase 1.1.1.10 L-xylulose reductase 1.1.1.11 D-arabinitol 4-dehydrogenase 1.1.1.12 L-arabinitol 4-dehydrogenase 1.1.1.13 L-arabinitol 2-dehydrogenase 1.1.1.14 L-iditol 2-dehydrogenase 1.1.1.15 D-iditol 2-dehydrogenase 1.1.1.16 galactitol 2-dehydrogenase 1.1.1.17 mannitol-1-phosphate 5-dehydrogenase 1.1.1.18 inositol 2-dehydrogenase 1.1.1.19 glucuronate reductase 1.1.1.20 glucuronolactone reductase 1.1.1.21 aldehyde reductase 1.1.1.22 UDP-glucose 6-dehydrogenase 1.1.1.23 histidinol dehydrogenase 1.1.1.24 quinate dehydrogenase 1.1.1.25 shikimate dehydrogenase 1.1.1.26 glyoxylate reductase 1.1.1.27 L-lactate dehydrogenase 1.1.1.28 D-lactate dehydrogenase 1.1.1.29 glycerate dehydrogenase 1.1.1.30 3-hydroxybutyrate dehydrogenase 1.1.1.31 3-hydroxyisobutyrate dehydrogenase 1.1.1.32 mevaldate reductase 1.1.1.33 mevaldate reductase (NADPH) 1.1.1.34 hydroxymethylglutaryl-CoA reductase (NADPH) 1.1.1.35 3-hydroxyacyl-CoA
    [Show full text]
  • Cloning, Expression, and Characterization of a New Glycosaminoglycan Lyase from Microbacterium Sp
    marine drugs Article Cloning, Expression, and Characterization of a New Glycosaminoglycan Lyase from Microbacterium sp. H14 Junhao Sun 1,2,3, Xu Han 1,2,3, Guanrui Song 1,2,3, Qianhong Gong 1,2,3,* and Wengong Yu 1,2,3,* 1 School of Medicine and Pharmacy, Ocean University of China, 5 Yushan Road, Qingdao 266003, China; [email protected] (J.S.); [email protected] (X.H.); [email protected] (G.S.) 2 Laboratory for Marine Drugs and Bioproducts, Qingdao National Laboratory for Marine Science and Technology, 1 Wenhai Road, Qingdao 266237, China 3 Provincial Key Laboratory of Glycoscience and Glycotechnology, Ocean University of China, 5 Yushan Road, Qingdao 266003, China * Correspondence: [email protected] (Q.G.); [email protected] (W.Y.); Tel.: +86-532-8203-2067 (Q.G.); +86-532-8203-1680 (W.Y.) Received: 8 November 2019; Accepted: 28 November 2019; Published: 2 December 2019 Abstract: Glycosaminoglycan (GAG) lyase is an effective tool for the structural and functional studies of glycosaminoglycans and preparation of functional oligosaccharides. A new GAG lyase from Microbacterium sp. H14 was cloned, expressed, purified, and characterized, with a molecular weight of approximately 85.9 kDa. The deduced lyase HCLaseM belonged to the polysaccharide lyase (PL) family 8. Based on the phylogenetic tree, HCLaseM could not be classified into the existing three subfamilies of this family. HCLaseM showed almost the same enzyme activity towards hyaluronan (HA), chondroitin sulfate A (CS-A), CS-B, CS-C, and CS-D, which was different from reported GAG lyases. HCLaseM exhibited the highest activities to both HA and CS-A at its optimal temperature (35 ◦C) and pH (pH 7.0).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0240226A1 Mathur Et Al
    US 20150240226A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0240226A1 Mathur et al. (43) Pub. Date: Aug. 27, 2015 (54) NUCLEICACIDS AND PROTEINS AND CI2N 9/16 (2006.01) METHODS FOR MAKING AND USING THEMI CI2N 9/02 (2006.01) CI2N 9/78 (2006.01) (71) Applicant: BP Corporation North America Inc., CI2N 9/12 (2006.01) Naperville, IL (US) CI2N 9/24 (2006.01) CI2O 1/02 (2006.01) (72) Inventors: Eric J. Mathur, San Diego, CA (US); CI2N 9/42 (2006.01) Cathy Chang, San Marcos, CA (US) (52) U.S. Cl. CPC. CI2N 9/88 (2013.01); C12O 1/02 (2013.01); (21) Appl. No.: 14/630,006 CI2O I/04 (2013.01): CI2N 9/80 (2013.01); CI2N 9/241.1 (2013.01); C12N 9/0065 (22) Filed: Feb. 24, 2015 (2013.01); C12N 9/2437 (2013.01); C12N 9/14 Related U.S. Application Data (2013.01); C12N 9/16 (2013.01); C12N 9/0061 (2013.01); C12N 9/78 (2013.01); C12N 9/0071 (62) Division of application No. 13/400,365, filed on Feb. (2013.01); C12N 9/1241 (2013.01): CI2N 20, 2012, now Pat. No. 8,962,800, which is a division 9/2482 (2013.01); C07K 2/00 (2013.01); C12Y of application No. 1 1/817,403, filed on May 7, 2008, 305/01004 (2013.01); C12Y 1 1 1/01016 now Pat. No. 8,119,385, filed as application No. PCT/ (2013.01); C12Y302/01004 (2013.01); C12Y US2006/007642 on Mar. 3, 2006.
    [Show full text]
  • CS Lyases: Structure, Activity, and Applications in Analysis and the Treatment of Diseases
    Robert J. Linhardt*, Fikri Y. Avci*, Toshihiko Toida†, Yeong Shik Kim‡, and Miroslaw Cygler} *Department of Chemistry and Chemical Biology Biology and Chemical and Biological Engineering Rensselaer Polytechnic Institute, Troy, New York 12180 †Graduate School of Pharmaceutical Sciences Chiba University, Chiba 263‐8522, Japan ‡Natural Products Research Institute, College of Pharmacy Seoul National University, Seoul 110‐460, Korea }Biotechnology Research Institute, NRC, Montreal Quebec H4P2R2, Canada CS Lyases: Structure, Activity, and Applications in Analysis and the Treatment of Diseases I. Chondroitin Sulfate Glycosaminoglycans _______________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________ Glycosaminoglycans (GAGs) are a family of highly sulfated, complex mixture of linear polysaccharides that display a wide array of biological activities (Boneu, 1996; Jackson et al., 1991). GAGs can be classified into four basic types—hyaluronan, chondroitin/dermatan sulfates (CS/DS), hepa- rin/heparan sulfate, and keratan sulfate (Capila and Linhardt, 2002; Esko and Selleck, 2002; Iozzo, 1998; Linhardt and Toida, 2004). Chondroitin/dermatan sulfates are the focus of this chapter. Chondroitin/dermatan sulfates are linear, polydisperse GAGs with a repeating core of disaccharide structure composed of a D‐glucopyranosyl uronic
    [Show full text]
  • Structural and Kinetic Studies of Heparinase II and Chondroitinase ABC
    Glycosaminoglycan Degradation - Structural and Kinetic Studies of Heparinase II and Chondroitinase ABC David Shaya, M.Sc. Doctor of Philosophy Department of Biochemistry McGill University Montreal, Quebec, Canada August 2008 A thesis submitted to McGill University in partial fulfillment of the requirements of the degree of Doctor of Philosophy Copyright 2008, David Shaya All rights reserved. ABSTRACT Glycosaminoglycans (GAGs) are linear, heterogeneous, negatively charged polysaccharides, common within the extracellular matrix (ECM) and at the cell-surfaces of all metazoan cells. Apart from their structural importance to the integrity of the ECM, GAGs are also fundamental modulators of various biological processes at the level of cells (i.e. adhesion, signaling and proliferation), tissue (i.e. inflammation, wound repair, tissue morphogenesis and organogenesis) and organism (i.e. cancer and developmental processes). The biological activities of GAGs are intricately linked to their turnover. Niche-adapted microorganisms express GAG-degrading enzymes, allowing them to process GAGs for nutritional purposes, both for themselves and for their mammalian hosts. In particular, bacterial GAG lyases cleave the glycosidic bond next to the uronic acid present in GAGs, through a β-elimination mechanism that yields disaccharide products with a saturated 4-deoxy-α-L-threo- hex-4-enopyranosyluronic acid (∆UA). Among the lyasses, heparinase II (HepII) and chondroitinase ABC (ChonABC) possess the striking ability to degrade GAGs regardless of their uronic acid epimer. HepII degrades both heparin and heparan sulfate, whereas ChonABC degrades both chondroitin sulfate and dermatan sulfate. This research is aimed at providing insight into the catalytic mechanism and the substrate specificity of these two enzymes at the molecular level.
    [Show full text]